BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24785399)

  • 1. A Community Jury on PSA screening: what do well-informed men want the government to do about prostate cancer screening--a qualitative analysis.
    Rychetnik L; Doust J; Thomas R; Gardiner R; Mackenzie G; Glasziou P
    BMJ Open; 2014 Apr; 4(4):e004682. PubMed ID: 24785399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men's knowledge about and intentions to participate in PSA screening.
    Thomas R; Glasziou P; Rychetnik L; Mackenzie G; Gardiner R; Doust J
    BMJ Open; 2014 Dec; 4(12):e005691. PubMed ID: 25539779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should women aged 70-74 be invited to participate in screening mammography? A report on two Australian community juries.
    Degeling C; Barratt A; Aranda S; Bell R; Doust J; Houssami N; Hersch J; Sakowsky R; Entwistle V; Carter SM
    BMJ Open; 2018 Jun; 8(6):e021174. PubMed ID: 29903796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "What should happen before asymptomatic men decide whether or not to have a PSA test?" A report on three community juries.
    Degeling C; Rychetnik L; Pickles K; Thomas R; Doust JA; Gardiner RA; Glasziou P; Newson AJ; Carter SM
    Med J Aust; 2015 Oct; 203(8):335. PubMed ID: 26465698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSA testing for men at average risk of prostate cancer.
    Armstrong BK; Barry MJ; Frydenberg M; Gardiner RA; Haines I; Carter SM
    Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involving a Citizens' Jury in Decisions on Individual Screening for Prostate Cancer.
    Mosconi P; Colombo C; Satolli R; Carzaniga S; ;
    PLoS One; 2016; 11(1):e0143176. PubMed ID: 26751212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All care, but whose responsibility? Community juries reason about expert and patient responsibilities in prostate-specific antigen screening for prostate cancer.
    Degeling C; Carter SM; Rychetnik L
    Health (London); 2016 Sep; 20(5):465-84. PubMed ID: 27491944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for prostate cancer.
    Ilic D; Neuberger MM; Djulbegovic M; Dahm P
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
    JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
    Gulati R; Gore JL; Etzioni R
    Ann Intern Med; 2013 Feb; 158(3):145-53. PubMed ID: 23381039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PSA testing dilemma: GPs' reports of consultations with asymptomatic men: a qualitative study.
    Clements A; Watson E; Rai T; Bukach C; Shine B; Austoker J
    BMC Fam Pract; 2007 Jun; 8():35. PubMed ID: 17593306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prostate cancer screening using prostate-specific antigen: The views of general and laboratory physicians].
    Giménez N; Filella X; Gavagnach M; Allué JA; Pedrazas D; Ferrer F;
    Semergen; 2018 Sep; 44(6):409-419. PubMed ID: 29574008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-screening Discussions and Prostate-Specific Antigen Testing for Prostate Cancer Screening.
    Li J; Zhao G; Hall IJ
    Am J Prev Med; 2015 Aug; 49(2):259-63. PubMed ID: 25997905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National evidence on the use of shared decision making in prostate-specific antigen screening.
    Han PK; Kobrin S; Breen N; Joseph DA; Li J; Frosch DL; Klabunde CN
    Ann Fam Med; 2013; 11(4):306-14. PubMed ID: 23835816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar perspectives on prostate cancer screening value and new guidelines across patient demographic and PSA level subgroups: A qualitative study.
    Partin MR; Lillie SE; White KM; Wilt TJ; Chrouser KL; Taylor BC; Burgess DJ
    Health Expect; 2017 Aug; 20(4):779-787. PubMed ID: 27807905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.
    Bancroft EK; Page EC; Brook MN; Thomas S; Taylor N; Pope J; McHugh J; Jones AB; Karlsson Q; Merson S; Ong KR; Hoffman J; Huber C; Maehle L; Grindedal EM; Stormorken A; Evans DG; Rothwell J; Lalloo F; Brady AF; Bartlett M; Snape K; Hanson H; James P; McKinley J; Mascarenhas L; Syngal S; Ukaegbu C; Side L; Thomas T; Barwell J; Teixeira MR; Izatt L; Suri M; Macrae FA; Poplawski N; Chen-Shtoyerman R; Ahmed M; Musgrave H; Nicolai N; Greenhalgh L; Brewer C; Pachter N; Spigelman AD; Azzabi A; Helfand BT; Halliday D; Buys S; Ramon Y Cajal T; Donaldson A; Cooney KA; Harris M; McGrath J; Davidson R; Taylor A; Cooke P; Myhill K; Hogben M; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Dias A; Dudderidge T; Eccles DM; Green K; Eyfjord J; Falconer A; Foster CS; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Lilja H; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra AV; Moynihan C; Ni Raghallaigh H; Rennert G; Collier R; ; Offman J; Kote-Jarai Z; Eeles RA
    Lancet Oncol; 2021 Nov; 22(11):1618-1631. PubMed ID: 34678156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.
    Carlsson S; Assel M; Sjoberg D; Ulmert D; Hugosson J; Lilja H; Vickers A
    BMJ; 2014 Mar; 348():g2296. PubMed ID: 24682399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Men's preferences and trade-offs for prostate cancer screening: a discrete choice experiment.
    Howard K; Salkeld GP; Patel MI; Mann GJ; Pignone MP
    Health Expect; 2015 Dec; 18(6):3123-35. PubMed ID: 25382490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.
    Martin RM; Donovan JL; Turner EL; Metcalfe C; Young GJ; Walsh EI; Lane JA; Noble S; Oliver SE; Evans S; Sterne JAC; Holding P; Ben-Shlomo Y; Brindle P; Williams NJ; Hill EM; Ng SY; Toole J; Tazewell MK; Hughes LJ; Davies CF; Thorn JC; Down E; Davey Smith G; Neal DE; Hamdy FC;
    JAMA; 2018 Mar; 319(9):883-895. PubMed ID: 29509864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.